Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Income from Continuing Operations (2016 - 2025)

Viking Therapeutics' Income from Continuing Operations history spans 12 years, with the latest figure at 157703000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 345.56% year-over-year to 157703000.0; the TTM value through Dec 2025 reached 359638000.0, down 227.0%, while the annual FY2025 figure was 359638000.0, 227.0% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 157703000.0 at Viking Therapeutics, down from 90789000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12351000.0 in Q4 2021 and bottomed at 157703000.0 in Q4 2025.
  • The 5-year median for Income from Continuing Operations is 20892500.0 (2022), against an average of 33958450.0.
  • The largest annual shift saw Income from Continuing Operations fell 10.44% in 2023 before it tumbled 345.56% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 12351000.0 in 2021, then tumbled by 58.29% to 19551000.0 in 2022, then dropped by 25.72% to 24579000.0 in 2023, then tumbled by 44.0% to 35394000.0 in 2024, then plummeted by 345.56% to 157703000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Income from Continuing Operations are 157703000.0 (Q4 2025), 90789000.0 (Q3 2025), and 65541000.0 (Q2 2025).